300583SZSE

Announcement on Subsidiary Receiving European CEP Certificate for Chemical API

Saito Biotech Co., Ltd.··2 pages

✨ AI Summary

Shandong Cretto Bio-Tech Co., Ltd. announced its subsidiary, Shandong Srui Pharmaceutical Co., Ltd., received a European CEP certificate from EDQM for Methylprednisolone API. This allows international sales, enhancing market competitiveness. The certificate is valid for five years from March 24, 2026.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Shandong Cretto Bio-Tech Co., Ltd. Announcement on Subsidiary Receiving European CEP Certificate for Chemical API

The company and its board of directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Shandong Cretto Bio-Tech Co., Ltd. (hereinafter referred to as "the Company") announced that its holding subsidiary, Shandong Srui Pharmaceutical Co., Ltd. (hereinafter referred to as "Srui Pharmaceutical"), recently received a Certificate of Suitability to the monographs of the European Pharmacopoeia (hereinafter referred to as "CEP Certificate") issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM") for its chemical raw material drug. The relevant situation is hereby announced as follows:

I. Information on the Registration Certificate for the Raw Material Drug

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.